This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Acer (ACER) to Get Acquired by Zevra for $91M, Stock Up
by Zacks Equity Research
Acer (ACER) surges as Zevra Therapeutics offers to acquire it for approximately $91 million.
Outlook's (OTLK) Shares Decline on CRL for Wet AMD Candidate
by Zacks Equity Research
Outlook's (OTLK) shares decline as it receives a complete response letter for Lytenava (ONS-5010), treating wet age-related macular degeneration.
Zai Lab (ZLAB) Up on Breakthrough Therapy Tag for Oncology Drug
by Zacks Equity Research
Zai Lab (ZLAB) gains on receiving Breakthrough Therapy designation for repotrectinib from the Center for Drug Evaluation of the National Medical Products Administration in China.
Merck's (MRK) Keytruda Receives EU Nod in Gastric Cancer
by Zacks Equity Research
Following the approval, Merck's (MRK) Keytruda is the first immunotherapy approved in the EU for first-line treatment for HER2-positive advanced gastric cancer in adults whose tumors express PD-L1.
Apellis (APLS) Dips on Layoffs Amid Syfovre Safety Issues
by Zacks Equity Research
Apellis (APLS) plans to initiate restructuring plans to strengthen its commercial portfolio and curb cash burn.
J&J (JNJ) Seeks Full FDA Nod for Balversa in Urothelial Cancer
by Zacks Equity Research
J&J (JNJ) submits a supplemental new drug application to the FDA for full approval of Balversa to treat urothelial carcinoma.
Invivyd (IVVD) Stock Rises 18% in 3 Months: Here's Why
by Zacks Equity Research
Invivyd's (IVVD) shares rallied almost 18% over the past three months, owing to promising developments in its monoclonal antibody candidate, VYD222, designed to prevent symptomatic COVID-19 infection.
PDS Biotech's (PDSB) Shares Up 12% in a Month: Here's Why
by Zacks Equity Research
Shares of PDS Biotech (PDSB) show an upward trajectory as the company progresses toward initiating the late-stage development of its lead pipeline candidate.
Esperion (ESPR) Aims to Expand Key Drug Labels for Growth
by Zacks Equity Research
Esperion's (ESPR) non-statin approved drugs uptake has continued to be the growth driver since launch. However, the company is currently facing a conflict with its partner, Daiichi Sankyo, regarding milestone payments.
J&J (JNJ) Seeks Full FDA Nod for Rybrevant in Lung Cancer
by Zacks Equity Research
J&J's (JNJ) FDA filing is based on a late-stage study showing that treatment with Rybrevant plus chemotherapy improved progression-free survival in certain NSCLC patients.
Here's Why You Should Add Corcept (CORT) Stock to Your Portfolio
by Zacks Equity Research
Corcept (CORT), a top-ranked stock, is witnessing incremental sales in its only marketed product, Korlym. It is also making good progress with its promising set of pipeline candidates.
Bionomics (BNOX) Up on Positive Updates on PTSD & SAD Candidate
by Zacks Equity Research
Bionomics (BNOX) gains as it provides updates on further development of its lead pipeline candidate, BNC210, developed for post-traumatic stress disorder and social anxiety disorder.
Fulcrum (FULC) Up as FDA Lifts Clinical Hold on SCD Candidate
by Zacks Equity Research
Fulcrum's (FULC) shares surge as the FDA lifts the clinical hold it had earlier placed on its pipeline candidate FTX-6058, to treat patients with sickle cell disease.
Apellis (APLS) Updates on Safety Concerns for Syfovre
by Zacks Equity Research
Apellis' (APLS) shares rise as the company provides updates on safety concerns regarding Syfovre, approved for the treatment of geographic atrophy.
J&J (JNJ) to Keep 9.5% Stake in Kenvue Post Share Exchange
by Zacks Equity Research
J&J's (JNJ) offer to exchange its shares for the shares of Kenvue, its recently-separated consumer healthcare business, gets oversubscribed. The exchange ratio is 8.0324 for every share of J&J.
Timber (TMBR) to Get Acquired by LEO Pharma for $36M, Stock Up
by Zacks Equity Research
Timber (TMBR) surges as LEO Pharma offers to acquire it for approximately $36 million.
Anebulo (ANEB) Gains on Positive FDA Response for ANEB-001
by Zacks Equity Research
Anebulo (ANEB) gains on positive FDA response for the phase III development of its lead candidate ANEB-001 for treating patients with acute cannabinoid intoxication.
Calliditas (CALT) Up as sNDA for Tarpeyo Gets Priority Review
by Zacks Equity Research
Calliditas (CALT) soars as the supplement new drug application seeking to convert accelerated approval of Tarpeyo delayed-release capsule to full approval gets accepted by the FDA.
Pieris (PIRS) Up On Receiving Milestone Payment From Partner
by Zacks Equity Research
Pieris (PIRS) soars as partner Boston Pharmaceuticals initiated early-stage study of PRS-342/BOS-342, triggering an undisclosed milestone payment to the former.
Wall Street Analysts See a 213.78% Upside in Annovis Bio, Inc. (ANVS): Can the Stock Really Move This High?
by Zacks Equity Research
The mean of analysts' price targets for Annovis Bio, Inc. (ANVS) points to a 213.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Biogen (BIIB) Beats on Q1 Earnings, Ends Some Research Programs
by Zacks Equity Research
Biogen (BIIB) beats first-quarter estimates for earnings and sales. It maintains its 2023 guidance. Stock drops in pre-market trading.
Best Momentum Stocks to Buy for April 21st
by Zacks Equity Research
ANVS, ACLX and WOR made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on April 21, 2023.
New Strong Buy Stocks for April 21st
by Zacks Equity Research
WOR, RYI, ANVS, ACLX and SIEGY have been added to the Zacks Rank #1 (Strong Buy) List on April 21, 2023.
Best Momentum Stocks to Buy for April 18th
by Zacks Equity Research
VRCA, BZ and ANVS made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on April 87, 2023.
Wall Street Analysts Think Annovis Bio, Inc. (ANVS) Could Surge 190.96%: Read This Before Placing a Bet
by Zacks Equity Research
The consensus price target hints at a 191% upside potential for Annovis Bio, Inc. (ANVS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.